4//SEC Filing
Duchemin Jeffrey 4
Accession 0001209191-19-022619
CIK 0001123494other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:56 PM ET
Size
10.5 KB
Accession
0001209191-19-022619
Insider Transaction Report
Form 4
Duchemin Jeffrey
Chief Executive Officer
Transactions
- Award
Common Stock
2019-03-07+113,034→ 793,528 total - Award
Stock option (right to buy)
2019-03-07+271,139→ 271,139 totalExercise: $3.79Exp: 2029-03-07→ Common Stock, par value $0.01 per share (271,139 underlying) - Award
Common Stock
2019-03-07+56,517→ 850,045 total
Footnotes (5)
- [F1]Represents a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023.
- [F2]Includes (a) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (b) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (c) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (d) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; (e) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which if earned shall vest in equal installments on May 24, 2019, 2020 and 2021, and are contingent upon achievement of a performance condition tied to relative total shareholder return; and (f) 263,497 shares of common stock held by the Reporting Person.
- [F3]Represents a deferred stock award of 56,517 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on March 7, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from March 7, 2019 to the earlier of (i) March 7, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.
- [F4]Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above.
- [F5]The options vest in four equal installments on January 1, 2020, 2021, 2022 and 2023.
Documents
Issuer
HARVARD BIOSCIENCE INC
CIK 0001123494
Entity typeother
Related Parties
1- filerCIK 0001585223
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 4:56 PM ET
- Size
- 10.5 KB